Developer docs
API playgroundTry for free, no card

Search company profiles

XCancer Research

Full company profile

uuid006fg4z

Namestring
XCancer Research
Legal namestring
XCancer
Websiteurl
xcancer.com
Company typeenum
Private
Founded yearint
2010
Descriptiontext

XCancer Research is a privately-held clinical research and services consortium headquartered in Omaha, Nebraska, focused on oncology theranostics—the pairing of diagnostic imaging with targeted radiopharmaceutical therapy for personalized cancer treatment. The flagship operating asset is the XCancer Omaha clinic, founded in 2010 by Dr. Luke Nordquist, which has become a globally recognized destination for prostate cancer care and research, treating more than 450 patients per month drawn from over 40 U.S. states and multiple countries, and contributing to 20+ First-in-World clinical advancements including landmark work in Ga-68 PSMA PET imaging and Lu-177 PSMA therapy.

The consortium architecture comprises nine operating divisions spanning clinical care (XCancer Omaha), clinical trial conduct (XCancer Research Network), proprietary trial software (XCancerSuite), a global trial information and education platform (TheranosticTrials.org), sponsor-facing consulting (XCancer Consulting), radiation safety and regulatory services (XCancer Health Physics Services), a nonprofit foundation with international reach (XCancer Foundation), a merchandise storefront (XCancer Store), and an awareness initiative via motorsport racing (XCancer Motorsports). Technology is organized around two core digital assets: XCancerSuite, which enables rapid trial activation and data management at community cancer centers, and TheranosticTrials.org, a centralized hub with real-time statistics and educational resources covering every theranostic clinical trial globally. The Health Physics Services unit adds regulatory and radiation safety consulting with 30+ years of nuclear medicine expertise.

Revenue is generated primarily through professional services: per-patient clinical trial participation fees (including Phase II–III registrational trials such as the Phase III AMPLIFY trial with Clarity Pharmaceuticals), consulting engagements with pharmaceutical sponsors, CROs, and biotech innovators, regulatory/safety consulting for radiopharmaceutical programs, and ancillary merchandise revenue flowing through the foundation. The go-to-market model is hybrid and channeled through three vectors: (1) enterprise-level relationships with pharmaceutical sponsors and CROs for trial conduct and consulting, (2) direct patient care at the Omaha flagship, and (3) a national community oncology network that enables trial decentralization across the U.S. Customer concentration is split among individual prostate cancer patients, pharmaceutical/biotech trial sponsors, and community cancer centers as network participants. The company is founder-led by Dr. Luke Nordquist (CEO), with no disclosed external venture or private equity backing.

Short descriptiontext

XCancer Research is a private, founder-led clinical research consortium in Omaha that conducts oncology theranostic trials, operates a destination prostate cancer clinic, runs a community cancer center network, and sells proprietary trial software and consulting to pharma sponsors.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersOmaha, United States
HQ citystring
Omaha
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oncology clinical trials, radiopharmaceutical research, theranostic drug development, prostate cancer care, clinical trial management
Industry3 codes
PRIMARYHLAKAFAB
Medical Oncology
SECONDARYHLACAGAH
Oncology Pathways & Precision Medicine Decision Support
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools
SECONDARYHLALAGAH
Oncology Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)
NAICS code3 codes
  • Medical and Diagnostic Laboratories62151
  • Diagnostic Imaging Centers621512
  • Other Scientific and Technical Consulting Services54169
SIC code3 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Health Services8000
  • Services-Medical Laboratories8071
Product category
Oncology Clinical Research Services
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Clinical Trial Services
TypeProfessional Services
Description

XCancer provides clinical trial conduct services through its Omaha clinic and research network, participating in Phase II-III registrational trials for radiopharmaceutical companies.

xcancer.com
2XCancer Consulting
TypeProfessional Services
Description

Consulting services offered to pharmaceutical sponsors, CROs, and biotech innovators for designing, scaling, and executing prostate cancer and theranostic programs. Led by Dr. Luke Nordquist with over 50 radiopharmaceutical trials led experience.

xcancer.com
3XCancer Foundation & Merchandise
TypeAffiliate Referral
Description

XCancer Store sells merchandise with proceeds supporting the XCancer Foundation's mission to expand access to life-saving cancer innovations globally.

xcancer.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2B and B2C
B2B and B2C
Offering typeServices
Services
Brand1 of 8 records shown
1TheranosticTrials.Org
Description

World's leading platform for comprehensive access to cancer theranostic clinical trials, serving as a centralized hub connecting researchers, clinicians, industry partners, patients, and advocates across the global theranostics ecosystem

xcancer.com
+7 more records
Core offering1 text field

XCancer is a consortium of companies that conducts oncology clinical trials and provides site management, patient enrollment, regulatory oversight, and data management services for radiopharmaceutical and theranostic therapies. Its offerings span direct prostate cancer patient care at the flagship Omaha clinic, expert consulting for pharmaceutical sponsors and CROs, a national network empowering community cancer centers to run trials, radiation safety/health physics consulting, and proprietary digital platforms (XCancerSuite for trial activation and TheranosticTrials.org for theranostic trial discovery).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 450+ patients served monthly at single Omaha location
+3 more records
Product overview1 text field

XCancer is a consortium of leading-edge companies united by a singular mission to fight cancer through Expanding the Reach of Cancer Innovations. The organization operates as a platform-plus-modules architecture centered around XCancerSuite (a proprietary software platform enabling rapid trial activation and data management) and TheranosticTrials.org (a global search engine for radiopharmaceutical clinical trials). These core digital platforms are complemented by clinical services including XCancer Omaha (a globally recognized prostate cancer treatment center), XCancer Consulting (expert consulting for pharmaceutical sponsors and CROs), and the XCancer Research Network (empowering community cancer centers to conduct cutting-edge trials). Additional supporting services include XCancer Health Physics Services (radiation safety consulting), XCancer Foundation (nonprofit for global access), XCancer Store (merchandise supporting the foundation), and XCancer Motorsports (awareness initiative through racing).

Product and service5 records
1XCancer Omaha Clinic
CategoryClinical Care Services
Description

Direct clinical services for prostate cancer patients including diagnostic imaging, radiopharmaceutical therapy (e.g., Lu-177 PSMA), and access to First-in-World clinical trials at the flagship Omaha, Nebraska clinic.

2XCancer Consulting
CategoryConsulting Services
Description

Expert consulting services led by Dr. Luke Nordquist for pharmaceutical sponsors, CROs, and biotech innovators on designing, scaling, and executing prostate cancer and theranostic/radiopharmaceutical clinical trial programs, with insight into community oncology and patient accrual.

3XCancer Research Network
CategoryClinical Trial Network Services
Description

Clinical trials network enabling community cancer centers across the United States to participate in cutting-edge oncology trials, providing trial identification, regulatory oversight, data management, contracts, finances, operations, and strategic guidance to launch trials within weeks.

4XCancer Health Physics Services
CategoryRegulatory & Safety Consulting
Description

Radiation safety and regulatory consulting for facilities developing or expanding radiopharmaceutical programs, including radiation protection program development, shielding evaluations, licensing assistance, equipment testing, and training.

5TheranosticTrials.org
CategoryClinical Trial Information Platform
Description

Centralized global platform providing comprehensive access to cancer theranostic clinical trial information, real-time statistics, and educational resources for researchers, clinicians, industry partners, patients, and advocates across the theranostics ecosystem.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-06
Description

Strategic partnership announced November 6, 2025 between Facet Life Sciences (a leader in regulatory strategy and drug development services) and XCancer (global leader in theranostic clinical research) to accelerate the development and approval of next-generation radiopharmaceutical therapies in oncology.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-05-29
Description

Clarity Pharmaceuticals, a clinical-stage radiopharmaceutical company focused on developing next-generation cancer treatments, partnered with XCancer for its registrational Phase III AMPLIFY trial of 64Cu-SAR-bisPSMA. XCancer Omaha successfully imaged the first patient in May 2025.

3DEForce Racing
Strategic tierMinorTypeGTM or Marketing Partner
Description

XCancer Motorsports is backed by DEForce Racing. The racing team competes in the USF Pro Championship Series, a pivotal step on the Road to Indy, raising awareness and support for cancer research through motorsport events.

xcancer.com
Strategic tierMinorTypeGTM or Marketing Partner
Description

Dr. Luke Nordquist appeared on the Oncidium Foundation Podcast discussing theranostics access and his referral guide for prostate cancer, contributing to patient education and awareness.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

IQVIA is the world's largest contract research organization, offering full-service clinical trial operations, site networks, and consulting. XCancer Consulting and XCancer Research Network compete for a portion of the same sponsor outsourcing budget that IQVIA captures, particularly for community oncology and radiopharmaceutical program design.

TypeOthers
Description

Lantheus is a radiopharmaceutical company with approved diagnostic and therapeutic agents (e.g., PYLARIFY for PSMA PET). As a likely sponsor of theranostic trials using XCancer-like sites, it is a relevant ecosystem participant and a potential enterprise customer for XCancer Consulting and XCancer Research Network.

TypeBroad incumbent
Description

Foundation Medicine, a subsidiary of Roche, provides comprehensive genomic profiling and connects patients to precision oncology trials. It is comparable to XCancer in using data platforms to bridge sponsors, clinicians, and patients in oncology trial access, though at much larger scale and with a broader (not theranostic-specific) indication focus.

TypeOthers
Description

Telix is a commercial-stage radiopharmaceutical company with approved PSMA imaging agents and an expanding theranostic pipeline. It is a probable future sponsor of community oncology trials and a natural counterpart to XCancer's specialized site and consulting services in the theranostics ecosystem.

5Sarah Cannon Research Institute
TypeDirect peer
Description

Sarah Cannon is one of the largest community oncology site networks in the US, conducting Phase I-III clinical trials across a wide range of cancer types. It directly parallels XCancer Research Network's model of enabling community cancer centers to participate in cutting-edge trials through centralized operational support.

TypeDirect peer
Description

US Oncology Research operates a large network of community-based oncology sites that enroll patients into sponsored clinical trials. Like XCancer Research Network, it provides the regulatory, data management, and operational backbone that allows community centers to run enterprise-grade trials, and serves the same pharmaceutical sponsor buyer.

TypeDirect peer
Description

START is a global network of early-phase oncology clinical trial sites, with deep expertise in radiopharmaceutical and theranostic trials. It is directly comparable to XCancer Omaha's specialized radiopharmaceutical trial capabilities and serves the same sponsor/CRO buyer seeking high-accrual, expert oncology sites.

TypeBroad incumbent
Description

ICON is a major global CRO with deep oncology and radiopharmaceutical trial capabilities acquired through PRA Health and other deals. It competes with XCancer's consulting and site-management offerings for enterprise oncology trial outsourcing engagements.

TypeOthers
Description

Clarity Pharmaceuticals is a clinical-stage radiopharmaceutical company developing next-generation PSMA-targeted agents including 64Cu-SAR-bisPSMA. It is a current XCancer partner/customer (Phase III AMPLIFY trial) and a leading indicator of sponsor demand for theranostic-focused sites, making it a key ecosystem participant rather than a direct competitor.

10Tempus AI
TypeEmerging player
Description

Tempus combines molecular profiling, data, and a clinical trial matching platform (Tempus One) for oncology. Its trial-matching and precision medicine infrastructure overlaps with TheranosticTrials.org and XCancerSuite, and it competes for the same sponsor attention in radiopharmaceutical/precision oncology program design.

Market position
Strengths1 record

Each record includes

Headline, Details, Source

Weaknesses1 record

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries9 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

XCancer Research

Oncology Clinical Research Servicesxcancer.com

XCancer Research is a private, founder-led clinical research consortium in Omaha that conducts oncology theranostic trials, operates a destination prostate cancer clinic, runs a community cancer center network, and sells proprietary trial software and consulting to pharma sponsors.

What XCancer Research does

XCancer Research is a privately-held clinical research and services consortium headquartered in Omaha, Nebraska, focused on oncology theranostics—the pairing of diagnostic imaging with targeted radiopharmaceutical therapy for personalized cancer treatment. The flagship operating asset is the XCancer Omaha clinic, founded in 2010 by Dr. Luke Nordquist, which has become a globally recognized destination for prostate cancer care and research, treating more than 450 patients per month drawn from over 40 U.S. states and multiple countries, and contributing to 20+ First-in-World clinical advancements including landmark work in Ga-68 PSMA PET imaging and Lu-177 PSMA therapy.

The consortium architecture comprises nine operating divisions spanning clinical care (XCancer Omaha), clinical trial conduct (XCancer Research Network), proprietary trial software (XCancerSuite), a global trial information and education platform (TheranosticTrials.org), sponsor-facing consulting (XCancer Consulting), radiation safety and regulatory services (XCancer Health Physics Services), a nonprofit foundation with international reach (XCancer Foundation), a merchandise storefront (XCancer Store), and an awareness initiative via motorsport racing (XCancer Motorsports). Technology is organized around two core digital assets: XCancerSuite, which enables rapid trial activation and data management at community cancer centers, and TheranosticTrials.org, a centralized hub with real-time statistics and educational resources covering every theranostic clinical trial globally. The Health Physics Services unit adds regulatory and radiation safety consulting with 30+ years of nuclear medicine expertise.

Revenue is generated primarily through professional services: per-patient clinical trial participation fees (including Phase II–III registrational trials such as the Phase III AMPLIFY trial with Clarity Pharmaceuticals), consulting engagements with pharmaceutical sponsors, CROs, and biotech innovators, regulatory/safety consulting for radiopharmaceutical programs, and ancillary merchandise revenue flowing through the foundation. The go-to-market model is hybrid and channeled through three vectors: (1) enterprise-level relationships with pharmaceutical sponsors and CROs for trial conduct and consulting, (2) direct patient care at the Omaha flagship, and (3) a national community oncology network that enables trial decentralization across the U.S. Customer concentration is split among individual prostate cancer patients, pharmaceutical/biotech trial sponsors, and community cancer centers as network participants. The company is founder-led by Dr. Luke Nordquist (CEO), with no disclosed external venture or private equity backing.

XCancer Research firmographics

Firmographics
Name
XCancer Research
Legal name
XCancer
Website
https://xcancer.com
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
11–50 employees
Short description
XCancer Research is a private, founder-led clinical research consortium in Omaha that conducts oncology theranostic trials, operates a destination prostate cancer clinic, runs a community cancer center network, and sells proprietary trial software and consulting to pharma sponsors.
Ownership category
akta.pro rank

XCancer Research industry classification

Industry
Product category
Oncology Clinical Research Services
NAICS
Medical and Diagnostic Laboratories (62151), Diagnostic Imaging Centers (621512), Other Scientific and Technical Consulting Services (54169)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Health Services (8000), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAKAFAB
Medical Oncology
SECONDARYHLACAGAH
Oncology Pathways & Precision Medicine Decision Support
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools
SECONDARYHLALAGAH
Oncology Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)

Keywords

  • Oncology clinical trials
  • Radiopharmaceutical research
  • Theranostic drug development
  • Prostate cancer care
  • Clinical trial management

Where XCancer Research is headquartered

Location

Headquarters

HQ city
Omaha
HQ country
United States
HQ region
North America

Offices1 record

Markets served

XCancer Research business model

Business model
GTM type
B2B and B2C
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Clinical Trial Services: XCancer provides clinical trial conduct services through its Omaha clinic and research network, participating in Phase II-III registrational trials for radiopharmaceutical companies.
  2. XCancer Consulting: Consulting services offered to pharmaceutical sponsors, CROs, and biotech innovators for designing, scaling, and executing prostate cancer and theranostic programs. Led by Dr. Luke Nordquist with over 50 radiopharmaceutical trials led experience.
  3. XCancer Foundation & Merchandise: XCancer Store sells merchandise with proceeds supporting the XCancer Foundation's mission to expand access to life-saving cancer innovations globally.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

XCancer Research product offering

Product offering

Core offering

XCancer is a consortium of companies that conducts oncology clinical trials and provides site management, patient enrollment, regulatory oversight, and data management services for radiopharmaceutical and theranostic therapies. Its offerings span direct prostate cancer patient care at the flagship Omaha clinic, expert consulting for pharmaceutical sponsors and CROs, a national network empowering community cancer centers to run trials, radiation safety/health physics consulting, and proprietary digital platforms (XCancerSuite for trial activation and TheranosticTrials.org for theranostic trial discovery).

Product overview

XCancer is a consortium of leading-edge companies united by a singular mission to fight cancer through Expanding the Reach of Cancer Innovations. The organization operates as a platform-plus-modules architecture centered around XCancerSuite (a proprietary software platform enabling rapid trial activation and data management) and TheranosticTrials.org (a global search engine for radiopharmaceutical clinical trials). These core digital platforms are complemented by clinical services including XCancer Omaha (a globally recognized prostate cancer treatment center), XCancer Consulting (expert consulting for pharmaceutical sponsors and CROs), and the XCancer Research Network (empowering community cancer centers to conduct cutting-edge trials). Additional supporting services include XCancer Health Physics Services (radiation safety consulting), XCancer Foundation (nonprofit for global access), XCancer Store (merchandise supporting the foundation), and XCancer Motorsports (awareness initiative through racing).

Differentiator

Problem solved

Functional benefit

Brands

  • TheranosticTrials.Org: World's leading platform for comprehensive access to cancer theranostic clinical trials, serving as a centralized hub connecting researchers, clinicians, industry partners, patients, and advocates across the global theranostics ecosystem
  • XCancer Consulting
  • XCancer Research Network
  • XCancer Foundation
  • XCancer Store
  • XCancer Software
  • XCancer Health Physics Services
  • XCancer Motorsports

Products and services

  • XCancer Omaha Clinic Direct clinical services for prostate cancer patients including diagnostic imaging, radiopharmaceutical therapy (e.g., Lu-177 PSMA), and access to First-in-World clinical trials at the flagship Omaha, Nebraska clinic.
  • XCancer Consulting Expert consulting services led by Dr. Luke Nordquist for pharmaceutical sponsors, CROs, and biotech innovators on designing, scaling, and executing prostate cancer and theranostic/radiopharmaceutical clinical trial programs, with insight into community oncology and patient accrual.
  • XCancer Research Network Clinical trials network enabling community cancer centers across the United States to participate in cutting-edge oncology trials, providing trial identification, regulatory oversight, data management, contracts, finances, operations, and strategic guidance to launch trials within weeks.
  • XCancer Health Physics Services Radiation safety and regulatory consulting for facilities developing or expanding radiopharmaceutical programs, including radiation protection program development, shielding evaluations, licensing assistance, equipment testing, and training.
  • TheranosticTrials.org Centralized global platform providing comprehensive access to cancer theranostic clinical trial information, real-time statistics, and educational resources for researchers, clinicians, industry partners, patients, and advocates across the theranostics ecosystem.

Quantifiable outcome

  • 450+ patients served monthly at single Omaha location
  • +3 more outcomes

Companies that use XCancer Research

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles4 records

XCancer Research technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

XCancer Research partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • Facet Life SciencescoreStrategic or Co-development Partner · 6 November 2025Strategic partnership announced November 6, 2025 between Facet Life Sciences (a leader in regulatory strategy and drug development services) and XCancer (global leader in theranostic clinical research) to accelerate the development and approval of next-generation radiopharmaceutical therapies in oncology.
  • Clarity PharmaceuticalscoreStrategic or Co-development Partner · 29 May 2025Clarity Pharmaceuticals, a clinical-stage radiopharmaceutical company focused on developing next-generation cancer treatments, partnered with XCancer for its registrational Phase III AMPLIFY trial of 64Cu-SAR-bisPSMA. XCancer Omaha successfully imaged the first patient in May 2025.
  • DEForce RacingminorGTM or Marketing PartnerXCancer Motorsports is backed by DEForce Racing. The racing team competes in the USF Pro Championship Series, a pivotal step on the Road to Indy, raising awareness and support for cancer research through motorsport events.
  • Oncidium FoundationminorGTM or Marketing PartnerDr. Luke Nordquist appeared on the Oncidium Foundation Podcast discussing theranostics access and his referral guide for prostate cancer, contributing to patient education and awareness.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

XCancer Research competitors and assessment

Company assessment

Broad incumbents

  • IQVIA: IQVIA is the world's largest contract research organization, offering full-service clinical trial operations, site networks, and consulting. XCancer Consulting and XCancer Research Network compete for a portion of the same sponsor outsourcing budget that IQVIA captures, particularly for community oncology and radiopharmaceutical program design.
  • Foundation Medicine: Foundation Medicine, a subsidiary of Roche, provides comprehensive genomic profiling and connects patients to precision oncology trials. It is comparable to XCancer in using data platforms to bridge sponsors, clinicians, and patients in oncology trial access, though at much larger scale and with a broader (not theranostic-specific) indication focus.
  • ICON plc: ICON is a major global CRO with deep oncology and radiopharmaceutical trial capabilities acquired through PRA Health and other deals. It competes with XCancer's consulting and site-management offerings for enterprise oncology trial outsourcing engagements.

Others

  • Lantheus Holdings: Lantheus is a radiopharmaceutical company with approved diagnostic and therapeutic agents (e.g., PYLARIFY for PSMA PET). As a likely sponsor of theranostic trials using XCancer-like sites, it is a relevant ecosystem participant and a potential enterprise customer for XCancer Consulting and XCancer Research Network.
  • Telix Pharmaceuticals: Telix is a commercial-stage radiopharmaceutical company with approved PSMA imaging agents and an expanding theranostic pipeline. It is a probable future sponsor of community oncology trials and a natural counterpart to XCancer's specialized site and consulting services in the theranostics ecosystem.
  • Clarity Pharmaceuticals: Clarity Pharmaceuticals is a clinical-stage radiopharmaceutical company developing next-generation PSMA-targeted agents including 64Cu-SAR-bisPSMA. It is a current XCancer partner/customer (Phase III AMPLIFY trial) and a leading indicator of sponsor demand for theranostic-focused sites, making it a key ecosystem participant rather than a direct competitor.

Direct peers

  • Sarah Cannon Research Institute: Sarah Cannon is one of the largest community oncology site networks in the US, conducting Phase I-III clinical trials across a wide range of cancer types. It directly parallels XCancer Research Network's model of enabling community cancer centers to participate in cutting-edge trials through centralized operational support.
  • US Oncology Research: US Oncology Research operates a large network of community-based oncology sites that enroll patients into sponsored clinical trials. Like XCancer Research Network, it provides the regulatory, data management, and operational backbone that allows community centers to run enterprise-grade trials, and serves the same pharmaceutical sponsor buyer.
  • START (South Texas Accelerated Research Therapeutics): START is a global network of early-phase oncology clinical trial sites, with deep expertise in radiopharmaceutical and theranostic trials. It is directly comparable to XCancer Omaha's specialized radiopharmaceutical trial capabilities and serves the same sponsor/CRO buyer seeking high-accrual, expert oncology sites.

Emerging players

  • Tempus AI: Tempus combines molecular profiling, data, and a clinical trial matching platform (Tempus One) for oncology. Its trial-matching and precision medicine infrastructure overlaps with TheranosticTrials.org and XCancerSuite, and it competes for the same sponsor attention in radiopharmaceutical/precision oncology program design.

Market position

Strengths1 record

Weaknesses1 record

Competitive moat5 records

Key risks7 records

Key highlights6 records

Customer concentration

XCancer Research social profiles

Digital presence

XCancer Research financial estimates

Financial estimate

Revenue estimate

Valuation estimate

XCancer Research leadership team

Management profile

Number of profiles

Profiles2 records

XCancer Research subsidiaries and ownership

Company hierarchy

Subsidiaries9 records

XCancer Research funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

XCancer Research M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about XCancer Research

What does XCancer Research do?

XCancer is a consortium of companies that conducts oncology clinical trials and provides site management, patient enrollment, regulatory oversight, and data management services for radiopharmaceutical and theranostic therapies. Its offerings span direct prostate cancer patient care at the flagship Omaha clinic, expert consulting for pharmaceutical sponsors and CROs, a national network empowering community cancer centers to run trials, radiation safety/health physics consulting, and proprietary digital platforms (XCancerSuite for trial activation and TheranosticTrials.org for theranostic trial discovery).

Is XCancer Research a public or private company?

XCancer Research is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was XCancer Research founded?

XCancer Research was founded in 2010. It employs 11 to 50 people.

Where is XCancer Research based?

XCancer Research is headquartered in Omaha, United States, in the North America region.

How does XCancer Research make money?

Three revenue lines are on record. Clinical Trial Services are the primary driver. The others are XCancer Consulting and XCancer Foundation & Merchandise.

Who are XCancer Research's main competitors?

Broad incumbents on record are IQVIA, Foundation Medicine and ICON plc. Others are Lantheus Holdings, Telix Pharmaceuticals and Clarity Pharmaceuticals. Direct peers are Sarah Cannon Research Institute, US Oncology Research and START (South Texas Accelerated Research Therapeutics). Tempus AI is listed as an emerging player.

Does XCancer Research have an API?

No public API is recorded for XCancer Research.

What industry is XCancer Research in?

XCancer Research's product category is Oncology Clinical Research Services. Its primary akta.pro industry code is HLAKAFAB, Medical Oncology, with a secondary code of HLACAGAH, Oncology Pathways & Precision Medicine Decision Support. Its NAICS code is 62151 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BloombergHow Cancer Drug Trials Make Big Money for Doctors, HospitalsA clinic in Omaha, Nebraska, named XCancer, has been actively involved in conducting drug trials for prostate cancer, significantly earning from pharmaceutical companies. XCancer, along with physician Luke Nordquist, has managed over 200 trials and can open a trial much quicker than larger academic institutions, leveraging the lucrative nature of these studies as drug companies heavily invest in clinical trials, with projections suggesting an annual expenditure of $80 billion in oncology alone. The article raises concerns about the ethics of patient enrollment and the quality of trials being conducted amidst these financial incentives.MorningstarFacet Life Sciences and XCancer Announce Strategic Partnership to Advance Theranostic Clinical TrialsFacet Life Sciences and XCancer announced a strategic partnership to accelerate theranostic clinical trials in oncology. The collaboration combines Facet's regulatory expertise with XCancer's clinical trial network, aiming to streamline development and approval of radiopharmaceutical therapies.YahooFacet Life Sciences and XCancer Announce Strategic Partnership to Advance Theranostic Clinical TrialsFacet Life Sciences and XCancer announced a strategic partnership to accelerate development and approval of next-generation radiopharmaceutical therapies in oncology. The collaboration combines Facet's regulatory expertise with XCancer's clinical trial network, aiming to streamline pathways for precision diagnostics and therapeutics.PR NewswireFacet Life Sciences and XCancer Announce Strategic Partnership to Advance Theranostic Clinical TrialsFacet Life Sciences and XCancer announced a strategic partnership to accelerate the development and approval of next-generation radiopharmaceutical therapies in oncology. The collaboration integrates Facet's regulatory and drug development expertise with XCancer's theranostic clinical trial network and infrastructure to streamline pathways for sponsors. This alliance aims to remove barriers for clinical trial activation and expand patient access to precision medicine.